Skip to main content

Vermillion Increases Price Target on Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today updated a planned offering of its common stock to raise as much as $33.9 million.

In an amended S-1 filing with the US Securities and Exchange Commission, the Austin, Texas-based diagnostics company said that it plans to offer up to 4 million shares of its stock at a maximum price of $7.36 per share.

Roth Capital Partners, the underwriter on the planned offering, also has the option to purchase 600,000 shares to cover overallotments, if any.

Today's filing increases the total Vermillion hopes to raise in the offering by doubling the number of shares it plans to offer while lowering the share price. Two weeks ago, Vermillion originally filed its prospectus with a planned offering of 2,098,539 shares at a maximum price of $8.22 per share, to raise up to $17.3 million.

The company did not say how much in net proceeds are expected from the offering, but said that the funds will be used to expand into international markets, support clinical trials for its peripheral artery disease test, "pursue opportunities to diversity our product and service lines and offerings," and general corporate purposes.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.